[ad_1]
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical firm based with a mission to find, develop and commercialize modern, first-in-class medicines that meet important unmet medical wants, right this moment introduced it would maintain a convention name on Thursday, October 30, 2025, at 4:30 p.m. Japanese Time to debate monetary outcomes and supply a enterprise replace from the third quarter of 2025.
To take part within the convention name, please dial (877) 346-6112 (home) or (848) 280-6350 (worldwide) and ask to be joined into the Ardelyx name. Dwell audio of the convention name will probably be concurrently webcast and will probably be obtainable beneath the Buyers part of the corporate’s web site at www.ardelyx.com . The webcast will probably be archived and obtainable for replay for 30 days following the decision.
About Ardelyx
Ardelyx was based with a mission to find, develop and commercialize modern, first-in-class medicines that meet important unmet medical wants. Ardelyx has two business merchandise authorised in america, IBSRELA ® (tenapanor) and XPHOZAH ® (tenapanor). Ardelyx has agreements for the event and commercialization of tenapanor exterior of the U.S. Kyowa Kirin commercializes PHOZEVEL ® (tenapanor) for hyperphosphatemia in Japan. A New Drug Utility for tenapanor for hyperphosphatemia has been authorised in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For extra info, please go to https://ardelyx.com/ and join with us on X (previously generally known as Twitter) , LinkedIn and Fb .
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
[ad_2]
